ReviewFrontiers in pharmacology2026
The landscape of biased agonism in aryl hydrocarbon receptor signaling: current clues and future directions.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Microbiota Metabolite-Joint Axis: Mechanistic Insights and Therapeutic Targets for Osteoarthritis.Biomedicines · 2026Review
- Craniofacial and dental toxicity of dioxins: developmental phenotypes and mechanistic insights.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our understanding of the aryl hydrocarbon receptor (AhR) signaling pathway has significantly advanced since its initial discovery, revealing roles in both toxicology and normal physiological processes like immunity and organ development. However, key gaps remain concerning the precise mechanisms governing ligand-dependent canonical and non-canonical signaling. From a pharmacological standpoint, this involves the concept of functional selectivity, also known as biased agonism, where different ligands can selectively activate distinct downstream pathways, leading to different biological or toxicological outcomes. This paper reviews the current understanding of the formation, composition, and function of both cytosolic and nuclear AhR multiprotein complexes. We analyze the early and late cellular events that follow AhR ligand binding and explore new approaches aimed at the selective targeting of the AhR canonical and non-canonical signaling pathways for potential therapeutic benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.